全文获取类型
收费全文 | 3432篇 |
免费 | 193篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 106篇 |
妇产科学 | 28篇 |
基础医学 | 440篇 |
口腔科学 | 317篇 |
临床医学 | 351篇 |
内科学 | 590篇 |
皮肤病学 | 23篇 |
神经病学 | 312篇 |
特种医学 | 119篇 |
外科学 | 518篇 |
综合类 | 23篇 |
预防医学 | 173篇 |
眼科学 | 32篇 |
药学 | 347篇 |
中国医学 | 3篇 |
肿瘤学 | 230篇 |
出版年
2022年 | 20篇 |
2021年 | 24篇 |
2020年 | 36篇 |
2019年 | 43篇 |
2018年 | 66篇 |
2017年 | 53篇 |
2016年 | 43篇 |
2015年 | 38篇 |
2014年 | 70篇 |
2013年 | 144篇 |
2012年 | 148篇 |
2011年 | 150篇 |
2010年 | 71篇 |
2009年 | 71篇 |
2008年 | 144篇 |
2007年 | 133篇 |
2006年 | 162篇 |
2005年 | 147篇 |
2004年 | 140篇 |
2003年 | 139篇 |
2002年 | 128篇 |
2001年 | 121篇 |
2000年 | 124篇 |
1999年 | 112篇 |
1998年 | 37篇 |
1997年 | 34篇 |
1996年 | 27篇 |
1995年 | 39篇 |
1994年 | 33篇 |
1993年 | 31篇 |
1992年 | 74篇 |
1991年 | 64篇 |
1990年 | 60篇 |
1989年 | 68篇 |
1988年 | 78篇 |
1987年 | 84篇 |
1986年 | 65篇 |
1985年 | 83篇 |
1984年 | 47篇 |
1983年 | 56篇 |
1982年 | 29篇 |
1979年 | 39篇 |
1978年 | 41篇 |
1977年 | 33篇 |
1976年 | 28篇 |
1973年 | 26篇 |
1972年 | 28篇 |
1971年 | 21篇 |
1969年 | 20篇 |
1967年 | 25篇 |
排序方式: 共有3629条查询结果,搜索用时 15 毫秒
91.
Rebecka Hjort Emma Ahlqvist Per-Ola Carlsson Valdemar Grill Leif Groop Mats Martinell Bahareh Rasouli Anders Rosengren Tiinamaija Tuomi Bjørn Olav Åsvold Sofia Carlsson 《Diabetologia》2018,61(6):1333-1343
Aims/hypothesis
Excessive weight is a risk factor for type 2 diabetes, but its role in the promotion of autoimmune diabetes is not clear. We investigated the risk of latent autoimmune diabetes in adults (LADA) in relation to overweight/obesity in two large population-based studies.Methods
Analyses were based on incident cases of LADA (n?=?425) and type 2 diabetes (n?=?1420), and 1704 randomly selected control participants from a Swedish case–control study and prospective data from the Norwegian HUNT Study including 147 people with LADA and 1,012,957 person-years of follow-up (1984–2008). We present adjusted ORs and HRs with 95% CI.Results
In the Swedish data, obesity was associated with an increased risk of LADA (OR 2.93, 95% CI 2.17, 3.97), which was even stronger for type 2 diabetes (OR 18.88, 95% CI 14.29, 24.94). The association was stronger in LADA with low GAD antibody (GADA; <median) (OR 4.25; 95% CI 2.76, 6.52) but present also in LADA with high GADA (OR 2.14; 95% CI 1.42, 3.24). In the Swedish data, obese vs normal weight LADA patients had lower GADA levels, better beta cell function, and were more likely to have low-risk HLA-genotypes. The combination of overweight and family history of diabetes (FHD) conferred an OR of 4.57 (95% CI 3.27, 6.39) for LADA and 24.51 (95% CI 17.82, 33.71) for type 2 diabetes. Prospective data from HUNT indicated even stronger associations; HR for LADA was 6.07 (95% CI 3.76, 9.78) for obesity and 7.45 (95% CI 4.02, 13.82) for overweight and FHD.Conclusions/interpretation
Overweight/obesity is associated with increased risk of LADA, particularly when in combination with FHD. These findings support the hypothesis that, even in the presence of autoimmunity, factors linked to insulin resistance, such as excessive weight, could promote onset of diabetes.92.
Thrombin plays a central role in thrombus formation through its conversion of fibrinogen to fibrin and activation of platelets as well as amplifying its own generation by feedback activation via factors V, VIII, and XI. Consequently, thrombin represents a logical and promising target for therapeutic interventions against arterial and venous thromboembolic disorders. Ximelagatran is the first oral agent in the new class of direct thrombin inhibitors and is rapidly absorbed and bioconverted to the active moiety, melagatran, which inhibits fluid-phase and clot-bound thrombin with similar high potency. Binding to the active site of thrombin is direct and competitive and does not require the presence of co-factors. Inhibition of thrombin generation and platelet activation has been demonstrated in vitro with melagatran as well as ex vivo after oral administration of ximelagatran to healthy human volunteers. Oral ximelagatran dose dependently reduced the total thrombus area in an ex vivo flow chamber model of arterial thrombosis, reflecting the cumulative effect of inhibition of thrombin activity, thrombin generation, and platelet activation. Melagatran has also been shown to reduce thrombin-mediated inflammation in vitro. The combination of antithrombotic and anti-inflammatory activity with the practicality of oral dosing provided by ximelagatran represents an important new option for the treatment of arterial and venous thromboembolic disorders. 相似文献
93.
Hong Li Christopher Lelliott Karolina Ploj Martina Verolin-Johansson Björn Carlsson Erik Michaëlsson 《Metabolism: clinical and experimental》2008,57(12):1704-1710
Chronic inflammation and increased visceral adipose tissue (VAT) are key elements of the metabolic syndrome. Both are considered to play a pathogenic role in the development of liver steatosis and insulin resistance. The aim of the present study was to investigate the hypothesis that an inflamed intestine, induced both by diet and chemical irritation, could induce persistent inflammation in VAT. Female C57BL/6JOlaHsd mice were used. In study I, groups of mice (n = 6 per group) were given an obesity-inducing cafeteria diet (diet-induced obesity) or regular chow only (control) for 14 weeks. In study II, colitis in mice (n = 8) was induced by 3% dextran sulfate sodium in tap water for 5 days followed by 21 days of tap water alone. Healthy control mice (n = 8) had tap water only. At the end of the studies, all mice were killed; and blood and tissues were sampled and processed for analysis. Body weight of diet-induced obese mice was greatly increased, with evidence of systemic inflammation, insulin resistance, and liver steatosis. Tissue inflammation indexed by proinflammatory cytokine expression was recorded in liver, mesenteric fat, and proximal colon/distal ileum, but not in subcutaneous or perigonadal fat. In dextran sulfate sodium-induced colitis mice, mesenteric fat was even more inflamed than the colon, whereas a much milder inflammation was seen in liver and subcutaneous fat. The studies showed both diet- and colitis-initiated inflammation in mesenteric fat. Fat depots contiguous with intestine and their capacity for exaggerated inflammatory responses to conditions of impaired gut barrier function may account for the particularly pathogenic role of VAT in obesity-induced metabolic disorders. 相似文献
94.
We have investigated the effects of different patterns of administration of recombinant human growth hormone (rhGH) on weight
gain, organ growth, serum GH binding protein (GHBP) and insulin-like growth factor-l (IGF-1) levels in a series of studies
using hypophysectomized (Hx) or GH-deficient dwarf (dw/dw) rats. Animals were given rhGH either by subcutaneous (s.c.) injections
(1 or 2 per day) or s.c. infusions and rhlGF-1 (2 mg/kg/day) by s.c. infusion. In Hx rats, all rhGH regimes increased body
weight, tibial epiphyseal plate width, and organ weights in a dose-related manner. Dwarf rats showed a smaller growth response
to rhGH than Hx rats, whereas rhGH induced greater elevations in serum GHBP in drarf rats. Growth responses depended on the
pattern of rhGH administration (twice daily injections > continuous infusions > daily injections). The shape of the body growth
curves also differed; rhGH injections increased weight gain linearly, whereas infusions gave an initial rapid weight gain
which slowed with time (a curvilinear response). For both regimens, tibial epiphyseal plate width increased linearly with
rhGH dose but infusions were 5-fold more potent than daily injections. Spleen and thymus weights were markedly increased by
rhGH and were also affected by the pattern of GH exposure. At 5 mg rhGH/kg/day, thymus weights were 390±35 mg for injectionsvs. 613 ± 34 mg for infusions (P<0.001) compared with 248 ± 16 mg in vehicle-treated Hx controls. Infusions of rhlGF-1 also stimulated specific organ growth
but caused less weight gain. RhlGF-1 additively increased the weight gain caused by rhGH injections but not by rhGH infusions.
Circulating IGF-1 and GHBP levels were increased in a dose-dependent manner by rhGH infusion, whereas daily injections were
ineffective. Thus, differential organ growth could be related to the higher serum IGF-1 concentrations induced by continuous
rhGH administration. These studies show that whole body growth is best maintained by intermittent rhGH exposure, whereas,
paradoxically, differential organ growth is most pronounced with continuous rhGH administration. 相似文献
95.
96.
Hammond TG Carlsson L Davis AS Lynch WG MacKenzie I Redfern WS Sullivan AT Camm AJ 《Cardiovascular research》2001,49(4):741-750
OBJECTIVE: To assess current practice in the pharmaceutical industry for assessing the potential for QT interval prolongation by non-cardiovascular medicinal products. METHODS: The survey was based on responses from the Toxicology and (Safety) Pharmacology laboratories (a total of 74 laboratories) of 54 companies based in Europe, Japan/Asia and the USA, received between January and March 1999. RESULTS: All 54 companies conducted preclinical in vivo electrocardiography (EGG) evaluation of new active substances (NASs). Thirty of these companies also conducted in vitro cardiac electrophysiology studies on their compounds. The majority of in vivo work was done in conscious beagle dogs. There was no consistency within the industry in defining the magnitude of change in QT interval that is considered biologically important. Most companies considered a change greater than 10% to be important, although the design of the studies suggested that group sizes used may not give sufficient statistical power to detect this size of change. Bazett's formula was used by 41% of laboratories to correct QT for changes in heart rate, despite the fact that this formula is generally deemed to be unsuitable for use in dogs. For studies in anaesthetised dogs, the majority of laboratories used barbiturate anaesthesia, but researchers should be aware of the effects of this and some other anaesthetic agents on QT interval. As for in vitro cardiac electrophysiology, there was wide diversity in the testing methodologies, particularly with regard to the test species and tissue type. As with QT prolongation, there was no consensus on the degree of action potential prolongation to cause concern. For both in vitro and in vivo testing, the majority of companies tested a minimum of three dose (or concentration) levels in order to ascertain any dose-response relationship. CONCLUSIONS: The survey provides a snapshot of the practice in the industry prior to any internationally-agreed consensus on the most effective and efficient approaches to minimising the risk of QT prolongation by new drugs in man. It must be stated that for any given methodology, the 'majority view' in the industry is not necessarily best practice. 相似文献
97.
98.
Is CEA analysis of value in screening for recurrences after surgery for colorectal carcinoma? 总被引:2,自引:3,他引:2
Ulf Carlsson M.D. Jan Stewénius M.D. Dr. Göran Ekelund M.D. Lennart Leandoer M.D. Bertil Nosslin M.D. 《Diseases of the colon and rectum》1983,26(6):369-373
The progress of 139 patients operated upon for cure of colorectal carcinoma, was followed postoperatively with a standardized
protocol. A CEA test was performed for comparison with other parameters. Median observation time was four years. When an upper
limit for CEA of 7.5 μg/l was allowed, sensitivity was found to be 78 per cent, specificity 91 per cent, and predictive value
of an elevated CEA concentration, 83 per cent. In general, CEA measurement traced, recurrence six months before clinical diagnosis.
In only a few cases was recurrence first heralded by an abnormality in other blood chemistry test results. CEA may thus be
used in postoperative screening for recurrence even though most recurrences, when detected, are not curable.
Read at the meeting of the American Society of Colon and Rectal Surgeons, Boston, Massachusetts, June 5–9, 1983
Presented in part at The World Congresses of Gastroenterology (OMGE) and Coloproctology, Stockholm, Sweden, June 14–19, 1982. 相似文献
99.
Rustscheff S Norlander L Macellaro A Sjöstedt A Vene S Carlsson M 《Scandinavian journal of infectious diseases》2000,32(6):605-607
Serologically verified indigenous Q fever is described in a 52-y-old male, who presented with persistent fever, muscle and joint pain, headache and non-purulent cough. Institution of doxycycline resulted in prompt recovery. Coxiella burnetii was isolated from mouldy hay in a barn. The strain differs from previously isolated ones in Sweden. 相似文献
100.
Abstract
Aims/hypothesis. Higher NEFA concentrations predict Type II (non-insulin-dependent) diabetes mellitus but it is not known whether higher NEFA
concentrations are genetically determined or reflect coexisting obesity. To address this question we studied whether common
variants in two genes encoding for key regulators of lipolysis, the β
2- and β
3- adrenoceptors (B2AR and B3AR) are associated with NEFA concentrations and Type II diabetes. Methods. A total of 1054 Swedish subjects with varying degrees of glucose tolerance were genotyped for the Gln27Glu variant in the B2AR and for the Trp64Arg variant in the B3AR genes using PCR-RFLP. Results. The B2AR Gln27 allele was more frequent in 219 Type II diabetic patients than in 237 non-diabetic subjects (59.8 % vs 52.3
%; OR = 1.72, p = 0.02) while there was no significant difference in the frequency of the B3AR Arg64 allele. Subjects homozygous for the
protective alleles (Glu27 and Trp64) had, however, a lower prevalence of diabetes than subjects with other genotype combinations
(OR = 0.58, p = 0.03). Among sibling pairs discordant for the B2AR Gln27Glu polymorphism, siblings with an excess of the Gln27 allele had
higher fasting insulin (n = 217; p = 0.02) and NEFA concentrations (107 sex-matched pairs; p = 0.01) than siblings with an excess of the Glu27 allele. Among sibling pairs discordant for the B3AR Trp64Arg variant, siblings
with the Arg64 allele had higher 2 h glucose (n = 48; p = 0.01) and NEFA concentrations (16 pairs matched for sex; p < 0.04) than siblings with the Trp64Trp64 genotype. Conclusions/interpretation. Common variants in the β
2- and β
3- adrenoceptor genes are associated with increased fasting insulin and NEFA concentrations and could increase susceptibility
to Type II diabetes. [Diabetologia (2001) 44: 629–636]
Received: 30 November 2000 and in revised from: 15 January 2001 相似文献